New Market Research Report: Hong Kong Pharmaceuticals & Healthcare Report Q3 2014

BMI View: An a geing population in Hong Kong offers growth opportunities for pharmaceutical firms given the expected rise in demand for medicines and healthcare services. In addition, we highlight that public hospitals may not be able to keep up in the rise in demand for healthcare due to the lack of medical professionals and facilities, bring opportunities for private healthcare players.

Headline Expenditure Projections

* Pharmaceuticals : HKD11.24bn (USD1.45bn) in 2013 to HKD12.21bn (USD1.57bn) in 2014; +8.6% in local currency terms and US dollar terms. Forecast unchanged from Q214.
* Healthcare: HKD122.00bn (USD15.73bn) in 2013 to HKD131.57bn (USD16.93bn) in 2014; +7.8% in local currency terms and US dollar terms. Forecast unchanged from Q214.

Full Report Details at
- http://www.fastmr.com/prod/814463_hong_kong_pharmaceuticals_healthcare_report_q3.aspx?afid=301

Risk/Reward Ratings

Hong Kong's Pharmaceutical Risk/Reward Rating (RRR) score for Q314 is 65 out of 100 in our newly improved RRR system. The country scores above average for most indicators and sub-indicators, including per capita pharmaceutical expenditure, sector value growth and pensionable population. Consequently with this high score, Hong Kong is ranked fifth, above China, out of the 19 key Asia Pacific markets.

Key Trends And Developments

* In April 2014, the Hong Kong Breast Cancer Foundation compiled a database of around 13,000 breast cancer patients - around one-third of the total of those diagnosed with the disease - to better inform doctors of the disease. As of May, for the first time doctors will have access to an online database of local breast cancer patients. The foundation will make the database accessible to doctors on May 22. According to the foundation's founder Polly Cheung Suk-yee the database will help doctors to monitor the effects of traditional Chinese drugs and other treatments. After registering, doctors can access patients' details, such as age, the stage of their cancer and the type of tumour, and see how similar cases have been treated in the country.
* In March 2014, Extrawell...

The Hong Kong Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Hong Kong Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Hong Kong pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Hong Kong to test other views - a key input for successful budgeting and strategic business planning in the Hong Kong pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Hong Kong Pharmaceuticals & Healthcare Report Q3 2014
- Thailand Pharmaceuticals & Healthcare Report Q3 2014
- Nigeria Pharmaceuticals & Healthcare Report Q3 2014
- Australia Pharmaceuticals & Healthcare Report Q3 2014
- Central America Pharmaceuticals & Healthcare Report Q3 2014